美罗华一线治疗非霍奇金氏淋巴瘤复发后行自体造血干细胞移植(附1例报告)
出处
《现代肿瘤医学》
CAS
2007年第3期420-421,共2页
Journal of Modern Oncology
参考文献4
-
1Schn L.The impact of R-CHOP Oil survival in aggressive NHL:optimizing treatment outcomes[J].Investigator Update and Expert Forum,2004,8.
-
2张红雨,林桐榆,姜文奇,张力,黄慧强,夏忠军,孙晓非,何友兼,管忠震.美罗华联合化疗治疗侵袭性B细胞性非霍奇金淋巴瘤的临床分析[J].癌症,2004,23(12):1681-1686. 被引量:16
-
3Sweetenham JW.Diffuse large B-cell lymphoma:risk stratification and management of relapsed disease[J].Hematology,2005,252~259.
-
4Winter JN,Weller E,Homing SJ,et al.Rituximab alters the prognostic indicator profile in diffuse aggressive non-Hodgkin's lymphomas[J].Blood,2003,102:101.
二级参考文献22
-
1管忠震,喻俪华,黄小薇,徐光川,张力.小细胞肺癌以化疗为主的综合治疗观察——80例报告[J].癌症,1989,8(2):101-103. 被引量:10
-
2The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classification of non-Hodgkin s lymphomas: Summary and description of a working formaulation for clinical usage [J]. Cancer,1982,49:2112- 2135.
-
3Elias L,Portlock CS,Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide,adriamycin,vincristine and predinisone (CHOP) [J]. Cancer, 1978,42( 4) :1075- 1710.
-
4Fisher RI,Gaynor ER,Dahlberg S,et al. Comparison of a standard regimen(CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma [J]. N Engl J Med,1993,324(14):1002- 1006.
-
5Fisher RI,Gaynor ER,Dahlberg S,et al. A phase Ⅲ comparison of CHOP vs M-BACOP vs ProMACE-CytoBOM vs MACOP-B in patients with intermediate or high-grade non-Hodgkin's lymphoma: results of SWOG-8516(Intergroup 0067),the National High-priority Lymphoma Study [J]. Ann Oncol,1994,(suppl 2):91- 95.
-
6Bubien JK,Zhou LJ,Bell PD,et al. Transfection of the CD20 cell surface molecular into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes [J]. J Cell Biol,1993,121(5):1121- 1132.
-
7Leveille C,Al-Daccak R,Mourad W. CD20 is physically and functionally cou;led to MHC class Ⅱ and CD on human B cell lines [J]. Eur J Immunol,1999,29(1):65- 74.
-
8James JS,Dubs G. FDA approves new kind of lymphoma treatment. Food and Drug Administration [J]. AIDS Treat News,1997,5(284):2- 3.
-
9Coiffier B,Haioun C,Ketterer N,et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase Ⅱ study [J]. Blood,1998,92(6):1927- 1932.
-
10Shan D,Ledbetter JA,Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies [J]. Blood,1998,91(5):1644- 1652.
共引文献15
-
1廖丽昇,谢颖,陈为民.非霍奇金淋巴瘤中枢神经系统侵犯4例[J].白血病.淋巴瘤,2006,15(1):51-52.
-
2张俊萍,毛光华,冯慧晶.利妥昔单抗联合CHOP化疗方案治疗老年非霍奇金淋巴瘤二例并文献复习[J].白血病.淋巴瘤,2006,15(5):383-384. 被引量:3
-
3凌云华,陆益,吴洪斌.利妥昔单抗及其联用CHOP方案的不良反应和处理[J].药物不良反应杂志,2006,8(5):355-358. 被引量:11
-
4刘秀均,欧阳志钢,戴垚,刘小云,甄永苏.平阳霉素与抗Ⅳ型胶原酶单抗3G11联合使用的抗肿瘤作用[J].中华肿瘤防治杂志,2007,14(3):177-180. 被引量:2
-
5蒋为民,丁剑午,李春来,胡蓉环,兰琼玉.美罗华联合化疗治疗13例复发耐药B细胞性淋巴瘤疗效分析[J].江西医药,2007,42(12):1143-1145. 被引量:1
-
6聂玉玲,王晓敏.美罗华治疗弥漫性大B细胞淋巴瘤的研究进展[J].新疆医学,2008,38(2):105-109.
-
7黄燕华,龙凤娇,陶红梅,张亚利.美罗华联合CHOP方案治疗非霍奇金淋巴瘤的护理[J].中国实用医药,2009,4(29):161-162. 被引量:4
-
8陈彦帆,韦燕,龚建忠,赵善林,杨泽芳.CHOP与CHOEP方案治疗弥漫大B细胞性淋巴瘤疗效比较[J].实用癌症杂志,2009,24(6):656-657. 被引量:4
-
9罗帼英.利妥昔单抗联合化疗治疗恶性淋巴瘤的护理[J].当代护士(中旬刊),2010,17(6):40-41. 被引量:3
-
10苏坤.利妥昔单抗联合CHOP化疗方案治疗CD20阳性B细胞性非霍奇金淋巴瘤疗效观察[J].临床合理用药杂志,2012,5(22):14-17. 被引量:10